Trial site
Nemocnica na okraji mesta, n.o.
Partizánske, 95801, SlovakiaEU-13 widening countryNot linked to an institution yet
- 7running trials
- 5closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 23 trials
- Status
- Active, not recruiting5 trials
- Completed5 trials
- Not yet recruiting1 trial
- Recruiting1 trial
- Lead sponsor
- Pfizer3 trials
- AstraZeneca AB1 trial
- Bio-Thera Solutions Ltd.1 trial
- F. Hoffmann-La Roche AG1 trial
- Gilead Sciences1 trial
- and 5 more
Running trials
Not yet recruiting
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
NCT07340658· Phase 3· Rovi Pharmaceuticals Laboratories· Source
Recruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026· Phase 2· NGM Biopharmaceuticals, Inc· Source
Active, not recruiting
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369· Phase 3· mAbxience Research S.L.· Source
Active, not recruiting
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· Phase 3· Pfizer· Source
Active, not recruiting
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation
NCT04964934· Phase 3· AstraZeneca AB· Source
Active, not recruiting
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
NCT03390686· Phase 3· Prestige Biopharma Limited· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error